[HTML][HTML] ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …
[HTML][HTML] The emerging role of ferroptosis in intestinal disease
S Xu, Y He, L Lin, P Chen, M Chen, S Zhang - Cell Death & Disease, 2021 - nature.com
Ferroptosis is a newly recognised type of regulated cell death (RCD) characterised by iron-
dependent accumulation of lipid peroxidation. It is significantly distinct from other RCDs at …
dependent accumulation of lipid peroxidation. It is significantly distinct from other RCDs at …
[HTML][HTML] Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline–Update 2022
P Pimentel-Nunes, D Libânio, BAJ Bastiaansen… - …, 2022 - thieme-connect.com
ESGE recommends that the evaluation of superficial gastrointestinal (GI) lesions should be
made by an experienced endoscopist, using high definition white-light and …
made by an experienced endoscopist, using high definition white-light and …
[HTML][HTML] Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E–mutant metastatic colorectal cancer: updated survival results and …
J Tabernero, A Grothey, E Van Cutsem… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib
versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with …
versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with …
[HTML][HTML] Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) guideline–update 2020
The following recommendations for post-polypectomy colonoscopic surveillance apply to all
patients who had one or more polyps that were completely removed during a high quality …
patients who had one or more polyps that were completely removed during a high quality …
Colorectal cancer
E Dekker, PJ Tanis, JLA Vleugels, PM Kasi… - The Lancet, 2019 - thelancet.com
Several decades ago, colorectal cancer was infrequently diagnosed. Nowadays, it is the
world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing …
world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing …
[HTML][HTML] The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: a systematic review and meta-analysis
Tumor-infiltrating lymphocytes (TILs) are an important histopathologic feature of colorectal
cancer that confer prognostic information. Previous clinical and epidemiologic studies have …
cancer that confer prognostic information. Previous clinical and epidemiologic studies have …
[HTML][HTML] Blockade of GCH1/BH4 axis activates ferritinophagy to mitigate the resistance of colorectal cancer to erastin-induced ferroptosis
Q Hu, W Wei, D Wu, F Huang, M Li, W Li… - Frontiers in cell and …, 2022 - frontiersin.org
Ferroptosis, a type of cell death triggered by excessive accumulation of iron-dependent lipid
peroxidation, possesses an excellent potential in cancer treatment. However, many …
peroxidation, possesses an excellent potential in cancer treatment. However, many …
[PDF][PDF] Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study
Deep learning (DL) can accelerate the prediction of prognostic biomarkers from routine
pathology slides in colorectal cancer (CRC). However, current approaches rely on …
pathology slides in colorectal cancer (CRC). However, current approaches rely on …
Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II trial
S Cousin, C Cantarel, JP Guegan, C Gomez-Roca… - Clinical Cancer …, 2021 - AACR
Purpose: Regorafenib is synergistic with immune checkpoint inhibition in colorectal cancer
preclinical models. Patients and Methods: This was a single-arm, multicentric phase II trial …
preclinical models. Patients and Methods: This was a single-arm, multicentric phase II trial …